Leinco Technologies

Anti-Human GD2 (Dinutuximab)

Product Code:
 
LEI-G160
Product Group:
 
Primary Antibodies
Antibody Isotype:
 
Human IgG1κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
APN311
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Functional Study
Shipping:
 
2 - 8°C Wet Ice
Storage:
 
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C.?Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-G160-1.0mg1 mg£287.00
Quantity:
LEI-G160-5.0mg5 mg£729.00
Quantity:
LEI-G160-25mg25 mg£2,661.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
GD2 is a cell surface glycolipid present in low concentrations on skin, neural or peripheral nerve cell surfaces. GD2 is overexpressed on neuroblastoma cells, most melanoma, and some other tumors.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Humanized antibody derived from mouse clone ch14.18
Long Description:
Neuroblastoma is an extracranial childhood cancer that accounts for 12% of cancer deaths in children1. Neuroblastomas highly express the antigen GD2, a glycolipid which assists in the attachment of tumor cells to the extracellular matrix2. Dinutuximab is a mouse-human chimeric monoclonal antibody to disialoganglioside (GD2) 3. Engagement of dinutuximab with GD2 triggers antibody dependent cell cytotoxicity and complement dependent cytotoxicity, the effectiveness of which is increased by coadministration with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-12), and 13-cis retinoic acid (isotretinoin). Dinutuximab, also known as ch14.18, was developed as an IgG1 human/mouse chimeric switch variant of murine monoclonal antibody 14.18 4. Dinutuximab is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and κ light-chain. Dinutuximab is produced in the murine myeloma cell line SP2/O and has an approximate molecular weight of 150 kDa 5. Studies have also tested the efficacy of dinutuximab grown in Chinese hamster ovary (CHO) cells (ch14.18/CHO)6,7.
Purity:
?95% by SDS Page, ?95% monomer by analytical SEC
Target:
GD2

References

1. Aust Prescr. 43(6):212-213. 2020. 2. Hoy SM. Target Oncol. 11(2):247-253. 2016. 3. Dhillon S. Drugs. 75(8):923-927. 2015. 4. Mueller BM, Romerdahl CA, Gillies SD, et al. J Immunol. 144(4):1382?1386. 1990. 5. https:// www.unituxin.com/full-prescribing-information.pdf 6. Ladenstein R, Weixler S, Baykan B, et al. MAbs. 5(5):801-809. 2013. 7. Ladenstein R, P?tschger U, Valteau-Couanet D, et al. Lancet Oncol. 19(12):1617-1629. 2018. 8. Barker E, Mueller BM, Handgretinger R, et al. Cancer Res. 51(1):144?149. 1991. 9. Yu AL, Gilman AL, Ozkaynak MF, et al. N Engl J Med. 363(14):1324?1334. 2010.